PD-L1 expression is associated with advanced non-small cell lung cancer

Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhiquan, Mei, Jiandong, Liu, Lunxu, Wang, Guochen, Li, Zuosheng, Hou, Jingpu, Zhang, Qiuyang, You, Zongbing, Zhang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/
https://www.ncbi.nlm.nih.gov/pubmed/27446371
http://dx.doi.org/10.3892/ol.2016.4741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/
https://www.ncbi.nlm.nih.gov/pubmed/27446371
http://dx.doi.org/10.3892/ol.2016.4741

Ejemplares similares